mdmbchmica indolebased synthetic cannabinoid potent agonist receptor sold online designer mdmbchmica initially sold name mmbchminaca compound corresponding code name ie isopropyl instead tbutyl analogue mdmbchminaca identified designer drug market several commercial samples mdmbchmica found exclusively contain senantiomer based vibrational electronic circular dichroism spectroscopy xray sconfiguration tertleucinate group unsurprising since mdmbchmica likely synthesized abundant inexpensive l form appropriate tertleucinate reactant mdmbchmica acts highly potent full agonist receptor efficacy value nm approximately times lower nm twofold lower abchminaca mdmbchmicas main metabolic reactions comprise monohydroxylations hydrolysis carboxylic ester function total metabolites could identified seventyone serious adverse events including acute intoxications deaths germany hungary poland sweden united kingdom norway occurred nine european countries associated side effects unconsciousness coma hyperemesis nausea seizures convulsions tachycardia bradycardia mydriasis syncope spontaneous urinating defecating shortness breath somnolence respiratory acidosis metabolic acidosis collapse lower limbs paralysis chest pain aggression severe disturbance behaviour united states mdmbchmica schedule controlled mdmbchmica illegal austria canada croatia denmark estonia finland germany greece hungary latvia lithuania luxembourg norway portugal turkey uk sweden august european commission proposed ban mdmbchmica across european union february commission adopted implementing act banning mdmbchmica member states shall take necessary measures subject control measures criminal penalties later march mdmbchmica seizures member states european union reported european monitoring centre drugs drug addiction including kg seizure sic luxembourg december httpsenwikipediaorgwikimdmbchmica